MedTrace Logo

A Study To Investigate The Safety And Toleration Of Multiple Oral Doses Of PF-03654764 In Combination With Fexofenadine In Healthy Subjects

NCT01298505 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2019-02-11

No results posted yet for this study

Summary

The purpose of this study in heathy people is to investigate the safety, toleration and time course of PF-03654764 in the blood, following multiple doses given by mouth together with fexofenadine.

Conditions

  • Healthy

Interventions

DRUG

PF-03654764 2.5mg plus fexofenadine 60mg

PF-03654764 2.5mg plus fexofenadine 60mg twice daily for 7 days

DRUG

PF-03654764 5mg plus fexofenadine 60mg

PF-03654764 5mg plus fexofenadine 60mg twice daily for 7 days

DRUG

placebo

placebo given twice daily for 7 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-04
Primary Completion
2010-06-04
Completion
2010-06-04

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01298505 on ClinicalTrials.gov